Home

Glenmark Pharmaceuticals Ltd EPS

Image

Glenmark Pharmaceuticals Ltd

NSE: GLENMARK

EPS

₹ 46.71

Last updated on: Jul 15, 2025

Key Highlights

  • The Earning per Share of Glenmark Pharmaceuticals Ltd is ₹ 46.71 as of 15 Jul 25 .
  • The earning per share of Glenmark Pharmaceuticals Ltd changed from ₹ 5.31 to ₹ 0.16 over 8 quarters. This represents a CAGR of -82.64% .

Historical Earning per Share of Glenmark Pharmaceuticals Ltd

No data available

* All values are in

Company Fundamentals for Glenmark Pharmaceuticals Ltd

Market Cap

62,844 Cr

EPS

46.7

P/E Ratio (TTM)

47.7

P/B Ratio (TTM)

7.1

Day’s High

2247.7

Day’s Low

2196.05

DTE

0.3

ROE

14.9

52 Week High

2286.15

52 Week Low

1274.7

ROCE

16.8

Market Price of Glenmark Pharmaceuticals Ltd

1M

1Y

3Y

5Y

Monitoring Glenmark Pharmaceuticals Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
16 Jul 20252202.9
15 Jul 20252226.95
14 Jul 20252218.2
11 Jul 20252181.55
10 Jul 20251905.15
09 Jul 20251817.95
08 Jul 20251829.1
07 Jul 20251862.35
04 Jul 20251831.5
03 Jul 20251782.85

SWOT Analysis Of Glenmark Pharmaceuticals Ltd

Strength

4

che

Weakness

2

che

Opportunity

1

che

Threats

1

che

BlinkX Score for Glenmark Pharmaceuticals Ltd

Asset Value vs Market Value of Glenmark Pharmaceuticals Ltd

Market Value

62,845

Asset Value

Value addition

6.4 X

8,478

* All values are in ₹ crores

Competitive Comparison of EPS

Company
leftMarket Capright
Glenmark Pharmaceuticals Ltd62844
Sun Pharmaceutical Industries Ltd414533
Divis Laboratories Ltd180215
Cipla Ltd120428
Torrent Pharmaceuticals Ltd116405
Mankind Pharma Ltd109464

Historical Market Cap of Glenmark Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Revenue of Glenmark Pharmaceuticals Ltd

No data available

* All values are in crore

Historical EBITDA of Glenmark Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Net Profit of Glenmark Pharmaceuticals Ltd

No data available

* All values are in crore

Dividend Payout Over Time

No data available

Glenmark Pharmaceuticals Ltd News Hub

Glenmark Pharmaceuticals Ltd spurts 2.5%, rises for fifth straight session

Glenmark Pharmaceuticals Ltd gained for a fifth straight session today. The stock is quoting at Rs 1

Read more

21 Aug 24

Glenmark Pharmaceuticals Ltd soars 4.33%, rises for third straight session

Glenmark Pharmaceuticals Ltd rose for a third straight session today. The stock is quoting at Rs 163

Read more

19 Aug 24

Glenmark Pharma gains after American subsidiary launches Olopatadine generic

The solution is the generic version of 'Pataday Twice Daily Relief', which is distributed by Alcon L

Read more

19 Aug 24

Glenmark launches Olopatadine Hydrochloride Ophthalmic Solution

Glenmark Therapeutics Inc., USA (Glenmark) has launched Olopatadine Hydrochloride Ophthalmic Solutio

Read more

19 Aug 24

Document

Annual Reports

Annual Report 2024

dropdown
download

Credit Ratings

Credit Report 2024

dropdown
download

Concalls

June 2024

TranscriptPPT

May 2024

PPT

Sep 2023

PPT

Feb 2022

PPT

Nov 2021

PPT

Aug 2021

PPT

May 2021

PPT

FAQs for EPS of Glenmark Pharmaceuticals Ltd

What is the EPS of Glenmark Pharmaceuticals Ltd stock?

The Earnings Per Share (EPS) of Glenmark Pharmaceuticals Ltd is 46.71. An EPS is the amount of net income attributed to each share of a common stock.

How is Glenmark Pharmaceuticals Ltd EPS calculated?

The EPS of Glenmark Pharmaceuticals Ltd is calculated by dividing the net income by the number of outstanding shares. The formula is EPS = (Net Income - Dividends on Preferred Stock) / Average Outstanding Shares.

How often does Glenmark Pharmaceuticals Ltd report its EPS?

Glenmark Pharmaceuticals Ltd typically reports its EPS quarterly and annually, in conjunction with its financial statements and earnings reports.

What factors can influence Glenmark Pharmaceuticals Ltd EPS?

Factors that influence the EPS of Glenmark Pharmaceuticals Ltd include revenue changes, cost fluctuations, operational efficiency, tax rates, and one-time gains or losses.

Can Glenmark Pharmaceuticals Ltd EPS growth indicate future performance?

Yes, consistent growth in Glenmark Pharmaceuticals Ltd EPS can suggest strong financial health and effective management, potentially indicating positive future performance.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions